Reasons for discontinuation vary by psoriasis treatment

August 10, 2012 in Diseases, Conditions, Syndromes

Reasons for discontinuation vary by psoriasis treatment

The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

(HealthDay) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

Howa Yeung, from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted interviews of 1,095 with moderate-to-severe plaque psoriasis to assess 11 reasons for treatment discontinuation for all past treatments (2,231 total).

The authors found that the median treatment duration ranged from 6.0 to 20.5 months (P < 0.001). For each treatment there was a significantly different frequency of each reason cited for discontinuation. A loss of efficacy was more likely to be cited by patients who received etanercept (odds ratio [OR], 5.19) and adalimumab (OR, 2.10) than by those who received methotrexate. Side effects were less likely to be cited by patients who received etanercept (OR, 0.34), adalimumab (OR, 0.48), or ultraviolet B phototherapy (OR, 0.21) than by those who received methotrexate, and were more likely to be cited by those who received acitretin (OR, 1.56). Inability to afford treatment was more likely to be cited by patients who underwent ultraviolet B phototherapy (OR, 7.03).

"A broad range of clinically relevant, patient-oriented reasons may explain why patients discontinue treatments," the authors write. "These results may inform the development of and evidence-based strategies to improve treatment satisfaction and to maintain successful long-term control."

Several authors disclosed financial ties to the .

More information: Abstract
Full Text (subscription or payment may be required)

Journal reference: Journal of the American Academy of Dermatology search and more info website

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

xgrassboy99
Aug 11, 2012

Rank: not rated yet
I know it is Goofy. But, try Essential Oil.Melaleuca from doTerra is one of your best bets. It is really good at stopping the itching.
Rank not rated yet
Relevant PhysicsForums posts

More news stories

FDA warns of infections tied to Tennessee pharmacy

(AP)—Government health officials are investigating several health problems reported with potentially contaminated medications made by a Tennessee specialty pharmacy.

Diseases, Conditions, Syndromes created 15 hours ago | popularity not rated yet | comments 0

Comorbidities common with alopecia areata

(HealthDay)—Comorbid conditions often accompany alopecia areata, according to a study published online May 22 in JAMA Dermatology.

Diseases, Conditions, Syndromes created 16 hours ago | popularity not rated yet | comments 0

Top-ranked golfer beats scoliosis

(HealthDay)—As a world-class golfer, Stacy Lewis' accomplishments are remarkable. But it was a physical challenge in her childhood that defined her ascent to the top of her sport.

Diseases, Conditions, Syndromes created 17 hours ago | popularity not rated yet | comments 0

Saudi to send animal samples to US in coronavirus probe (Update)

Saudi Arabia said Friday it would send samples taken from animals possibly infected with a deadly SARS-like virus to the United States for testing in a bid to find the source of disease.

Diseases, Conditions, Syndromes created 20 hours ago | popularity not rated yet | comments 0

WHO voices deep concern over spread of SARS-like virus

The World Health Organization voiced deep concern Thursday over the SARS-like virus that has killed 22 people in less than a year, saying it might potentially spread more widely between humans.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity 5 / 5 (1) | comments 0


Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Are there atheists in foxholes? Study says they're the minority

Ernie Pyle – an iconic war correspondent in World War II – reportedly said "There are no atheists in foxholes." A new joint study between two brothers at Cornell and Virginia Wesleyan found that only ...

Help at hand for people with schizophrenia

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...